Shortage of Abatacept (Orencia®) Resolved – update
Update: August 28, 2024.
Bristol Myers Squibb (BMS), the manufacturer of Orencia (abatacept), has announced that the shortage of subcutaneous abatacept will be resolved as of the 30 August 2024.
Starting from 30 August 2024:
- The TGA medicine shortage notification for abatacept 125 mg single dose syringe will no longer be in place.
- The abatacept 125 mg single-dose syringe, BMS, China Stock approved under Section 19A will no longer be available.
- Normal ordering processes for both abatacept pre-filled syringe and ClickJect autoinjector can resume via the DHL online portal.
- Patients may switch back to, or new patients may be initiated on, any of the abatacept presentations as deemed appropriate by the treating physician.
Patients should consult with their healthcare providers for further information.
Discover more...
-
Parliamentary summit on better care for arthritis and musculoskeletal conditions
Click here to download the summit agenda Click here to download the communique Musculoskeletal conditions, including arthritis and back pain , affect around 7 million...
-
Arthritis Australia welcomes funding for kids with arthritis
Arthritis Australia has welcomed Australian Government funding announced in the federal budget for kids living with juvenile arthritis, including renewed funding for Arthritis Australia and...
-
Over 20 peak groups join Arthritis Australia’s call for urgent action on arthritis and musculoskeletal conditions.
Arthritis Australia and over 40 leading health stakeholders including over 20 peak bodies have issued a formal communique calling for urgent action to provide more...
Sign up to Arthritis Insights
Regular updates, news and research findings delivered to your inbox:
